REFERENCES
1. Bui A.L., Horwich T.B., Fonarow G.C. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011; 8: 30-41. DOI: https://doi.org/10.1038/nrcardio.2010.165
2. Reddy P., Dunn A.B. The effect of beta-blockers on health-related quality of life in patients with heart failure. Pharmacotherapy. 2000; 20: 679-89. DOI: https://doi.org/10.1592/phco.20.7.679.35178
3. Lewis E.F., Johnson P.A., Johnson W., Collins C., Griffin L., Stevenson L.W. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001; 20: 1016-24. DOI: https://doi.org/10.1016/s1053-2498(01)00298-4
4. Tsevat J., Weeks J.C., Guadagnoli E., Tosteson A.N., Mangi-one C.M., Pliskin J.S., et al. Using health-related quality-of-life information: clinical encounters, clinical trials, and health policy. J Gen Intern Med. 1994; 9: 576-82. DOI: https://doi.org/10.1007/bf02599287
5. US-FDA. Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry. URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/treatmentheart-failure-endpoints-drug-development-guidance-industry (date of access September 29, 2019)
6. McMurray J.J.V., Solomon S.D., Inzucchi S.E., Kober L.,Kosiborod M.N., Martinez F.A., et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995-2008. DOI: https://doi.org/10.1056/NEJMoa1911303
7. AstraZeneca. AstraZeneca Clinical Trials - Disclosure Commitment. URL: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure(date of access October 29, 2019)
8. McMurray J.J.V., DeMets D.L., Inzucchi S.E., Kober L.,Kosiborod M.N., Langkilde A.M., et al.; DAPA-HF Committees and Investigators. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail. 2019; 21: 1402-11. DOI: https://doi.org/10.1002/ejhf.1548
9. McMurray J.J.V., DeMets D.L., Inzucchi S.E., Kober L., Kosiborod M.N., Langkilde A.M., et al.; DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019; 21: 665-75. DOI: https://doi.org/10.1002/ejhf.1432
10. Green C.P., Porter C.B., Bresnahan D.R., Spertus J.A. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000; 35: 1245-55. DOI: https://doi.org/10.1016/s0735-1097(00)00531-3
11. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985; 4: 8790. DOI: https://doi.org/10.1002/sim.4780040112
12. Spertus J., Peterson E., Conard M.W., Heidenreich P.A., Krumholz H.M., Jones P., et al.; Cardiovascular Outcomes Research Consortium. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005; 150: 707-15. DOI: https://doi.org/10.1016/j.ahj.2004.12.010
13. Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 2001; 22: 102-10. DOI: https://doi.org/10.1016/s0197–2456(00)00134–3
14. Dewan P., Jhund P.S., Shen L., Petrie M.C., Abraham W.T., Atif Ali M., et al. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019; 21: 577-87. DOI: https://doi.org/10.1002/ejhf.1347
15. Nassif M.E., Windsor S.L., Tang F., Khariton Y., Husain M., Inzucchi S.E., et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: The DEFINE-HF Trial. Circulation. 2019; 140: 1463-76. DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.042929
16. Ekman I., Chassany O., Komajda M., Bohm M., Borer J.S., Ford I., et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011; 32: 2395-404. DOI: https://doi.org/10.1093/eurheartj/ehr343
17. Lewis E.F., Claggett B.L., McMurray J.J.V., Packer M.,Lefkowitz M.P., Rouleau J.L., et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017; 10: e003430.DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.116.003430
18. Flynn K.E., Pina I.L., Whellan D.J., Lin L., Blumenthal J.A., Ellis S.J., et al.; HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009; 301: 1451-9. DOI: https://doi.org/10.1001/jama.2009.457
19. Veazie P.J., Noyes K., Li Q., Hall W.J., Buttaccio A., Thevenet-Morrison K., et al. Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. J Am Coll Cardiol. 2012; 60: 1940-4. DOI: https://doi.org/10.1016/j.jacc.2012.06.054